Gastroenterology Therapeutics
1. Aciphex patent expiration
Treatment: Treatment of peptic ulcers
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5045552 | WAYLIS THERAP | Pyridine derivatives having anti-ulcerative activity |
May, 2013
(12 years ago) | |
|
US5045552 (Pediatric) | WAYLIS THERAP | Pyridine derivatives having anti-ulcerative activity |
Nov, 2013
(12 years ago) | |
Drugs and Companies using RABEPRAZOLE SODIUM ingredient
Market Authorisation Date: 29 May, 2002
Dosage: TABLET, DELAYED RELEASE
How can I launch a generic of ACIPHEX before it's drug patent expiration?
More Information on Dosage
ACIPHEX family patents
2. Aloxi patent expiration
Treatment: Prevention of postoperative nausea and vomiting; Prevention of chemotherapy-induced nausea and vomiting
ALOXI's oppositions filed in EPO
ALOXI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9125905 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US8598219 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
|
US8598219 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
| US5202333 | HELSINN HLTHCARE | Tricyclic 5-HT3 receptor antagonists |
Apr, 2015
(10 years ago) | |
|
US5202333 (Pediatric) | HELSINN HLTHCARE | Tricyclic 5-HT3 receptor antagonists |
Oct, 2015
(10 years ago) | |
| US9066980 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US8729094 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US9457021 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US7947725 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US7960424 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US8518981 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US9439854 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US8598218 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US9173942 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US9457020 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
| US7947724 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 11 months ago) | |
|
US7947724 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US7947725 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US7960424 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US8729094 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US8518981 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US8598218 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US9173942 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US9125905 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US9439854 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US9457020 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US9457021 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
|
US9066980 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 22, 2011 |
| New Indication(I-684) | May 27, 2017 |
| M(M-136) | May 27, 2017 |
| Pediatric Exclusivity(PED) | Nov 27, 2017 |
Drugs and Companies using PALONOSETRON HYDROCHLORIDE ingredient
Market Authorisation Date: 29 February, 2008
Dosage: INJECTABLE; CAPSULE
How can I launch a generic of ALOXI before it's drug patent expiration?
More Information on Dosage
ALOXI family patents
3. Amitiza patent
expiration
Treatment: Method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable exci...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8097653 | SUCAMPO PHARMA LLC | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(3 years ago) | |
| US8071613 | SUCAMPO PHARMA LLC | Anti-constipation composition |
Sep, 2020
(5 years ago) | |
| US8114890 | SUCAMPO PHARMA LLC | Anti-constipation composition |
Sep, 2020
(5 years ago) | |
| US8389542 | SUCAMPO PHARMA LLC | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(3 years ago) | |
| US5284858 | SUCAMPO PHARMA LLC | Prostaglandins E and anti ulcers containing same |
Jul, 2014
(11 years ago) | |
| US8088934 | SUCAMPO PHARMA LLC | Composition and method for stabilizing the same |
May, 2021
(4 years ago) | |
| US7064148 | SUCAMPO PHARMA LLC | Chloride channel opener |
Aug, 2022
(3 years ago) | |
| US6583174 | SUCAMPO PHARMA LLC | Composition and method for stabilizing the same |
Oct, 2020
(5 years ago) | |
| US6414016 | SUCAMPO PHARMA LLC | Anti-constipation composition |
Sep, 2020
(5 years ago) | |
| US7417067 | SUCAMPO PHARMA LLC | Composition and method for stabilizing the same |
Oct, 2020
(5 years ago) | |
| US8097649 | SUCAMPO PHARMA LLC | Composition and method for stabilizing the same |
Oct, 2020
(5 years ago) | |
| US6982283 | SUCAMPO PHARMA LLC | Method for treating drug-induced constipation |
Dec, 2022
(3 years ago) | |
| US7795312 | SUCAMPO PHARMA LLC | Method for treating abdominal discomfort |
Sep, 2024
(1 year, 3 months ago) | |
| US8748481 | SUCAMPO PHARMA LLC | Method for treating gastrointestinal disorder |
Sep, 2025
(4 months ago) | |
| US8779187 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(1 year, 14 days from now) | |
| US8026393 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Oct, 2027
(1 year, 9 months from now) | |
| US8338639 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(1 year, 14 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-670) | Apr 19, 2016 |
| M(M-225) | Apr 26, 2021 |
Drugs and Companies using LUBIPROSTONE ingredient
Market Authorisation Date: 29 April, 2008
Dosage: CAPSULE
How can I launch a generic of AMITIZA before it's drug patent expiration?
More Information on Dosage
AMITIZA family patents
4. Colazal patent expiration
Treatment: Treatment of ulcerative colitis
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7625884 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(7 months from now) | |
| US7452872 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(7 months from now) | |
|
US7452872 (Pediatric) | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Feb, 2027
(1 year, 1 month from now) | |
|
US7625884 (Pediatric) | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Feb, 2027
(1 year, 1 month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 20, 2013 |
| Pediatric Exclusivity(PED) | Jun 20, 2014 |
Drugs and Companies using BALSALAZIDE DISODIUM ingredient
Market Authorisation Date: 18 July, 2000
Dosage: CAPSULE
How can I launch a generic of COLAZAL before it's drug patent expiration?
More Information on Dosage
COLAZAL family patents
5. Dificid patent expiration
Treatment: Treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8586551 | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Jul, 2023
(2 years ago) | |
| US7378508 | CUBIST PHARMS LLC | Polymorphic crystalline forms of tiacumicin B |
Jul, 2027
(1 year, 6 months from now) | |
| US7863249 | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(1 year, 6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859510 | CUBIST PHARMS LLC | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(1 year, 6 months from now) | |
| US7906489 | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Mar, 2027
(1 year, 1 month from now) | |
|
US8586551 (Pediatric) | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Jan, 2024
(1 year, 11 months ago) | |
| US7863249 | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(1 year, 6 months from now) | |
| US9808530 | CUBIST PHARMS LLC | Composition of tiacumicin compounds |
May, 2034
(8 years from now) | |
|
US7378508 (Pediatric) | CUBIST PHARMS LLC | Polymorphic crystalline forms of tiacumicin B |
Jan, 2028
(2 years from now) | |
|
US7863249 (Pediatric) | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jan, 2028
(2 years from now) | |
|
US8859510 (Pediatric) | CUBIST PHARMS LLC | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jan, 2028
(2 years from now) | |
|
US7906489 (Pediatric) | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Sep, 2027
(1 year, 7 months from now) | |
|
US9808530 (Pediatric) | CUBIST PHARMS LLC | Composition of tiacumicin compounds |
Nov, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2016 |
| New Product(NP) | Jan 24, 2023 |
| New Patient Population(NPP) | Jan 24, 2023 |
| Pediatric Exclusivity(PED) | Jul 24, 2023 |
| Orphan Drug Exclusivity(ODE-367) | Jan 24, 2027 |
Drugs and Companies using FIDAXOMICIN ingredient
Market Authorisation Date: 24 January, 2020
Dosage: FOR SUSPENSION; TABLET
How can I launch a generic of DIFICID before it's drug patent expiration?
More Information on Dosage
DIFICID family patents
6. Emend patent expiration
Treatment: Treatment or prevention of emesis; Prevention of postoperative nausea and vomiting
EMEND's oppositions filed in EPO
EMEND IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214692 | MSD | Medical use for tachykinin antagonists |
Sep, 2012
(13 years ago) | |
| US5538982 | MSD | Medical use for tachykinin antagonists |
Jul, 2013
(12 years ago) | |
| US5719147 | MSD | Morpholine and thiomorpholine tachykinin receptor antagonists |
Apr, 2015
(10 years ago) | |
| US6096742 | MSD | Polymorphic form of a tachykinin receptor antagonist |
Jul, 2018
(7 years ago) | |
| US8258132 | MSD | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2013 |
| M(M-82) | Mar 19, 2013 |
| New Dosing Schedule(D-128) | Nov 12, 2013 |
| New Patient Population(NPP) | Apr 03, 2021 |
| New Dosing Schedule(D-155) | Feb 01, 2019 |
| Pediatric Exclusivity(PED) | Oct 03, 2021 |
| New Dosing Schedule(D-186) | May 02, 2025 |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 30 June, 2006
Dosage: CAPSULE
How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage
EMEND family patents
7. Emend patent expiration
Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)
EMEND's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6096742 | MSD MERCK CO | Polymorphic form of a tachykinin receptor antagonist |
Jul, 2018
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8258132 | MSD MERCK CO | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2013 |
| M(M-82) | Mar 19, 2013 |
| New Dosing Schedule(D-128) | Nov 12, 2013 |
| New Patient Population(NPP) | Apr 03, 2021 |
| New Dosing Schedule(D-155) | Feb 01, 2019 |
| Pediatric Exclusivity(PED) | Oct 03, 2021 |
| New Dosing Schedule(D-186) | May 02, 2025 |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 17 December, 2015
Dosage: FOR SUSPENSION
How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage
EMEND family patents
8. Emend patent expiration
Treatment: Prevention or treatment of nausea or emesis induced by a cancer chemotherapeutic agent
EMEND IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5512570 | MERCK AND CO INC | Treatment of emesis with morpholine tachykinin receptor antagonists |
Mar, 2014
(11 years ago) | |
| US5538982 | MERCK AND CO INC | Medical use for tachykinin antagonists |
Jul, 2013
(12 years ago) | |
| US7214692 | MERCK AND CO INC | Medical use for tachykinin antagonists |
Sep, 2012
(13 years ago) | |
| US5716942 | MERCK AND CO INC | Treatment of migraine with morpholine tachykinin receptor antagonists |
Feb, 2015
(10 years ago) | |
| US5691336 | MERCK AND CO INC | Morpholine compounds are prodrugs useful as tachykinin receptor antagonists |
Mar, 2019
(6 years ago) | |
|
US5691336 (Pediatric) | MERCK AND CO INC | Morpholine compounds are prodrugs useful as tachykinin receptor antagonists |
Sep, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2013 |
| M(M-82) | Mar 19, 2013 |
| New Dosing Schedule(D-128) | Nov 12, 2013 |
| New Patient Population(NPP) | Apr 03, 2021 |
| New Dosing Schedule(D-155) | Feb 01, 2019 |
| Pediatric Exclusivity(PED) | Oct 03, 2021 |
| New Dosing Schedule(D-186) | May 02, 2025 |
Drugs and Companies using FOSAPREPITANT DIMEGLUMINE ingredient
NCE-1 date: 03 October, 2020
Market Authorisation Date: 25 January, 2008
Dosage: POWDER
How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage
EMEND family patents
9. Entereg patent expiration
Treatment: A method for binding a peripheral opioid receptor; A method of treating or preventing ileus; Treating a subject undergoing abdominal surgery by administering alvimopan to accelerate the time to upper ...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5250542 | CUBIST PHARMS | Peripherally selective piperidine carboxylate opioid antagonists |
Mar, 2016
(9 years ago) | |
| US6469030 | CUBIST PHARMS | Methods for the treatment and prevention of ileus |
Nov, 2020
(5 years ago) | |
| US8645160 | CUBIST PHARMS | Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug |
Jun, 2029
(3 years from now) | |
| US8112290 | CUBIST PHARMS | Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug |
Jul, 2030
(4 years from now) | |
| US8946262 | CUBIST PHARMS | Methods of preventing and treating gastrointestinal dysfunction |
Feb, 2030
(4 years from now) | |
| US5434171 | CUBIST PHARMS | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
Dec, 2013
(12 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 20, 2013 |
| M(M-128) | Oct 18, 2016 |
Drugs and Companies using ALVIMOPAN ingredient
NCE-1 date: 20 May, 2012
Market Authorisation Date: 20 May, 2008
Dosage: CAPSULE
How can I launch a generic of ENTEREG before it's drug patent expiration?
More Information on Dosage
ENTEREG family patents
10. Ibsrela patent expiration
Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8969377 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(3 years from now) | |
| US12016856 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(3 years from now) | |
| US8541448 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Aug, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9006281 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
May, 2030
(4 years from now) | |
| US9408840 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder |
Dec, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2024 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: 13 September, 2023
Market Authorisation Date: 12 September, 2019
Dosage: TABLET
More Information on Dosage
IBSRELA family patents
11. Imagent patent expiration
Treatment: Method of use of imagent
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5798091 | VESSELON SPV LLC | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
Aug, 2015
(10 years ago) | |
| US6280704 | VESSELON SPV LLC | Ultrasonic imaging system utilizing a long-persistence contrast agent |
Jul, 2013
(12 years ago) | |
| US5605673 | VESSELON SPV LLC | Stabilized microbubble compositions for ultrasound |
Feb, 2014
(11 years ago) | |
| US5626833 | VESSELON SPV LLC | Ultrasound imaging method using microbubbles |
May, 2014
(11 years ago) | |
| US5695741 | VESSELON SPV LLC | Stable microbubble precursors |
Dec, 2014
(11 years ago) | |
| US6280705 | VESSELON SPV LLC | Kits & systems for ultrasonic imaging |
Jul, 2013
(12 years ago) | |
| US5639443 | VESSELON SPV LLC | Stabilized microbubble compositions |
Jun, 2014
(11 years ago) | |
| US5720938 | VESSELON SPV LLC | Systems for the formation of microbubbles |
Feb, 2015
(10 years ago) | |
| US6287539 | VESSELON SPV LLC | Methods of imaging using osmotically stabilized microbubble preparations |
Jul, 2013
(12 years ago) | |
Drugs and Companies using DIMYRISTOYL LECITHIN; PERFLEXANE ingredient
Market Authorisation Date: 31 May, 2002
Dosage: INJECTABLE
More Information on Dosage
IMAGENT family patents
12. Iqirvo patent expiration
Treatment: Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults who have had an inadequate response to udca, or as monotherapy in patients unable to tolerate u...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943661 | IPSEN | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof |
Sep, 2024
(1 year, 3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11857523 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US11331292 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US11185519 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12310935 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12295928 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12295927 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US7632870 | IPSEN | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |
Sep, 2024
(1 year, 3 months ago) | |
| US11850223 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12233038 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 10, 2029 |
| Orphan Drug Exclusivity(ODE-486) | Jun 10, 2031 |
Drugs and Companies using ELAFIBRANOR ingredient
NCE-1 date: 10 June, 2028
Market Authorisation Date: 10 June, 2024
Dosage: TABLET
More Information on Dosage
IQIRVO family patents
13. Linzess patent expiration
Treatment: Method of treating chronic idiopathic constipation in adult patients.; Method of treating of irritable bowel syndrome with constipation (ibs-c) in pediatric patients 7 years of age and older; Method o...
LINZESS's oppositions filed in EPO
Can you believe LINZESS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7304036 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Aug, 2026
(7 months from now) | |
| US7745409 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| US7704947 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| US8080526 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| US7371727 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8110553 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| US8933030 | ABBVIE | Treatments for gastrointestinal disorders |
Feb, 2031
(5 years from now) | |
| US8748573 | ABBVIE | Formulations comprising linaclotide |
Oct, 2031
(5 years from now) | |
| US9708371 | ABBVIE | Treatments for gastrointestinal disorders |
Aug, 2033
(7 years from now) | |
| US10702576 | ABBVIE | Stable formulations of linaclotide |
Aug, 2031
(5 years from now) | |
| US8802628 | ABBVIE | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration |
Oct, 2031
(5 years from now) | |
| US10675325 | ABBVIE | Stable formulations of linaclotide |
Aug, 2031
(5 years from now) | |
|
US8802628 (Pediatric) | ABBVIE | NA |
Apr, 2032
(6 years from now) | |
|
US7304036 (Pediatric) | ABBVIE | NA |
Feb, 2027
(1 year, 1 month from now) | |
|
US8748573 (Pediatric) | ABBVIE | NA |
Apr, 2032
(6 years from now) | |
|
US9708371 (Pediatric) | ABBVIE | NA |
Feb, 2034
(8 years from now) | |
|
US8933030 (Pediatric) | ABBVIE | NA |
Aug, 2031
(5 years from now) | |
|
US10675325 (Pediatric) | ABBVIE | NA |
Feb, 2032
(6 years from now) | |
|
US10702576 (Pediatric) | ABBVIE | NA |
Feb, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2017 |
| New Strength(NS) | Jan 25, 2020 |
| New Indication(I-921) | Jun 12, 2026 |
Drugs and Companies using LINACLOTIDE ingredient
NCE-1 date: 30 August, 2016
Market Authorisation Date: 25 January, 2017
Dosage: CAPSULE
How can I launch a generic of LINZESS before it's drug patent expiration?
More Information on Dosage
LINZESS family patents
14. Livdelzi patent expiration
Treatment: Treatment of primary biliary cholangitis (pbc)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7709682 | GILEAD SCIENCES INC | Lysine salts of 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives |
Sep, 2026
(8 months from now) | |
| US7301050 | GILEAD SCIENCES INC | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
Aug, 2026
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11596614 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| US11406611 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| US10272058 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| US9486428 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 14, 2029 |
| Orphan Drug Exclusivity(ODE-486) | Aug 14, 2031 |
Drugs and Companies using SELADELPAR LYSINE ingredient
NCE-1 date: 14 August, 2028
Market Authorisation Date: 14 August, 2024
Dosage: CAPSULE
More Information on Dosage
LIVDELZI family patents
15. Livmarli patent expiration
Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs); Treatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis...
Can you believe LIVMARLI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11497745 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(14 years from now) | |
| US11260053 | MIRUM | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
May, 2031
(5 years from now) | |
| US11229661 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(6 years from now) | |
| US11229647 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(14 years from now) | |
| US10512657 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(6 years from now) | |
| US11376251 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(6 years from now) | |
| US12350267 | MIRUM | NA |
Oct, 2032
(6 years from now) | |
| US12296050 | MIRUM | Pharmaceutical compositions comprising maralixibat and uses thereof |
Oct, 2043
(17 years from now) | |
| US11918578 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 13, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2026 |
| New Indication(I-938) | Mar 13, 2027 |
| Orphan Drug Exclusivity(ODE-379) | Sep 29, 2028 |
| Orphan Drug Exclusivity(ODE-429) | Mar 13, 2030 |
| ODE*(ODE*) | Mar 13, 2031 |
| Orphan Drug Exclusivity(ODE-471) | Mar 13, 2031 |
| Orphan Drug Exclusivity(ODE-490) | Jul 24, 2031 |
Drugs and Companies using MARALIXIBAT CHLORIDE ingredient
NCE-1 date: 29 September, 2025
Market Authorisation Date: 10 April, 2025
Dosage: TABLET; SOLUTION
More Information on Dosage
LIVMARLI family patents
16. Lotronex patent expiration
Treatment: For women with severe diarrhea-predominant irritable bowel syndrome (ibs)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5360800 | LEGACY PHARMA | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives |
Jan, 2013
(12 years ago) | |
| US6284770 | LEGACY PHARMA | Medicaments for the treatment of non-constipated female irritable bowel syndrome |
Oct, 2018
(7 years ago) | |
Drugs and Companies using ALOSETRON HYDROCHLORIDE ingredient
Market Authorisation Date: 09 February, 2000
Dosage: TABLET
How can I launch a generic of LOTRONEX before it's drug patent expiration?
More Information on Dosage
LOTRONEX family patents
17. Movantik patent expiration
Treatment: Treatment of opioid-induced constipation
MOVANTIK's oppositions filed in EPO
MOVANTIK IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7662365 | AVERITAS | Polymer conjugates of opioid antagonists |
Oct, 2022
(3 years ago) | |
| US7786133 | AVERITAS | Chemically modified small molecules |
Sep, 2028
(2 years from now) | |
| US9012469 | AVERITAS | Crystalline naloxol-peg conjugate |
Apr, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8617530 | AVERITAS | Polymer conjugates of opioid antagonists |
Oct, 2022
(3 years ago) | |
| US8067431 | AVERITAS | Chemically modified small molecules |
Dec, 2024
(1 year, 23 days ago) | |
| US7056500 | AVERITAS | Polymer conjugates of opioid antagonists |
Jun, 2024
(1 year, 6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 16, 2019 |
Drugs and Companies using NALOXEGOL OXALATE ingredient
NCE-1 date: 16 September, 2018
Market Authorisation Date: 16 September, 2014
Dosage: TABLET
How can I launch a generic of MOVANTIK before it's drug patent expiration?
More Information on Dosage
MOVANTIK family patents
18. Ocaliva patent expiration
Treatment: Treatment of primary biliary cholangitis (pbc); Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults with an inadequate response to udca, or as mono...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7138390 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Nov, 2022
(3 years ago) | |
| US10174073 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Jun, 2033
(7 years from now) | |
| USRE48286 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Feb, 2027
(1 year, 1 month from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8058267 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Feb, 2022
(3 years ago) | |
| US8377916 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Feb, 2022
(3 years ago) | |
| US10047117 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Sep, 2033
(7 years from now) | |
| US10758549 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(10 years from now) | |
| US10751349 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(10 years from now) | |
| US10052337 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(10 years from now) | |
| US9238673 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Jun, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2021 |
| Orphan Drug Exclusivity(ODE) | May 27, 2023 |
| Orphan Drug Exclusivity(ODE-119) | May 27, 2023 |
Drugs and Companies using OBETICHOLIC ACID ingredient
NCE-1 date: 27 May, 2020
Market Authorisation Date: 27 May, 2016
Dosage: TABLET
How can I launch a generic of OCALIVA before it's drug patent expiration?
More Information on Dosage
OCALIVA family patents
19. Protonix patent expiration
Treatment: Erosive esophagitis, hypersecretory conditions including zollinger-ellison syndrome, maintenance of healing of erosive esophagitis and reduction of symptoms in patients with gerd
PROTONIX IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5997903 | WYETH PHARMS | Oral-administration forms of a medicament containing pantoprazol |
Dec, 2016
(9 years ago) | |
|
US5997903 (Pediatric) | WYETH PHARMS | Oral-administration forms of a medicament containing pantoprazol |
Jun, 2017
(8 years ago) | |
| US7553498 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(1 year, 3 months ago) | |
| US7838027 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(1 year, 3 months ago) | |
| US7550153 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(1 year, 3 months ago) | |
| US7544370 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Jun, 2026
(4 months from now) | |
|
US7544370 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Dec, 2026
(10 months from now) | |
|
US7550153 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(9 months ago) | |
|
US7553498 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(9 months ago) | |
|
US7838027 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-614) | Nov 12, 2012 |
| M(M-54) | Nov 12, 2012 |
| Pediatric Exclusivity(PED) | May 12, 2013 |
Drugs and Companies using PANTOPRAZOLE SODIUM ingredient
Market Authorisation Date: 12 June, 2001
Dosage: FOR SUSPENSION, DELAYED RELEASE; TABLET, DELAYED RELEASE
How can I launch a generic of PROTONIX before it's drug patent expiration?
More Information on Dosage
PROTONIX family patents
20. Relistor patent expiration
Treatment: Treatment of opioid-induced constipation
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6559158 | SALIX | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
Nov, 2017
(8 years ago) | |
| US9180125 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(3 years from now) | |
| US9492445 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(3 years from now) | |
| US9724343 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(3 years from now) | |
| US8420663 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(3 years from now) | |
| US8956651 | SALIX | Oral formulations and lipophilic salts of methylnal trexone |
Mar, 2031
(5 years from now) | |
| US9314461 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(5 years from now) | |
| US10376505 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(5 years from now) | |
| US8524276 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(5 years from now) | |
| US10307417 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2013 |
| New Product(NP) | Jul 19, 2019 |
Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient
Market Authorisation Date: 19 July, 2016
Dosage: TABLET
How can I launch a generic of RELISTOR before it's drug patent expiration?
More Information on Dosage
RELISTOR family patents
21. Relistor patent expiration
Treatment: Treatment of opioid-induced constipation; Treatment of opioid-induced constipation (oic) in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its tre...
RELISTOR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420663 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(3 years from now) | |
| US6559158 | SALIX PHARMS | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
Nov, 2017
(8 years ago) | |
| US8822490 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(3 years from now) | |
| US10376584 | SALIX PHARMS | Stable pharmaceutical formulations of methylnaltrexone |
Apr, 2024
(1 year, 9 months ago) | |
| US12303592 | SALIX PHARMS | Formulations for parenteral delivery of compounds and uses thereof |
Aug, 2027
(1 year, 6 months from now) | |
| US8247425 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Dec, 2030
(4 years from now) | |
| US9492445 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(3 years from now) | |
| US8552025 | SALIX PHARMS | Stable methylnaltrexone preparation |
Apr, 2024
(1 year, 9 months ago) | |
| US9669096 | SALIX PHARMS | Stable pharmaceutical formulations of methylnaltrexone |
Apr, 2024
(1 year, 9 months ago) | |
| US9180125 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2013 |
| New Product(NP) | Jul 19, 2019 |
Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient
NCE-1 date: 24 April, 2012
Market Authorisation Date: 27 September, 2010
Dosage: SOLUTION
How can I launch a generic of RELISTOR before it's drug patent expiration?
More Information on Dosage
RELISTOR family patents
22. Rezdiffra patent expiration
Treatment: Treatment of adults with noncirrhotic nonalcoholic steatohepatitis (nash) with moderate to advanced liver fibrosis (consistent with stages f2 to f3 fibrosis)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11564926 | MADRIGAL | Methods of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(7 years from now) | |
| US9266861 | MADRIGAL | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(7 years from now) | |
| US7452882 | MADRIGAL | Thyroid hormone analogs |
Sep, 2026
(8 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11986481 | MADRIGAL | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(7 years from now) | |
| US10376517 | MADRIGAL | Methods of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(7 years from now) | |
| US12377104 | MADRIGAL | NA |
Feb, 2045
(19 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 14, 2029 |
Drugs and Companies using RESMETIROM ingredient
NCE-1 date: 14 March, 2028
Market Authorisation Date: 14 March, 2024
Dosage: TABLET
More Information on Dosage
REZDIFFRA family patents
23. Symproic patent expiration
Treatment: Treatment of opioid-induced constipation
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8536192 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Oct, 2026
(8 months from now) | |
| US8084460 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Jan, 2028
(2 years from now) | |
| USRE46375 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Oct, 2026
(8 months from now) | |
| USRE46365 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Feb, 2031
(5 years from now) | |
| US9108975 | BDSI | Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same |
Nov, 2031
(5 years from now) | |
| US10952968 | BDSI | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives |
May, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12350377 | BDSI | NA |
May, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 23, 2022 |
Drugs and Companies using NALDEMEDINE TOSYLATE ingredient
NCE-1 date: 23 March, 2021
Market Authorisation Date: 23 March, 2017
Dosage: TABLET
More Information on Dosage
SYMPROIC family patents
24. Terlivaz patent expiration
Treatment: A method to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10335452 | MALLINCKRODT IRELAND | Method of treating patients with hepatorenal syndrome type 1 |
Apr, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 14, 2027 |
| Orphan Drug Exclusivity(ODE-406) | Sep 14, 2029 |
Drugs and Companies using TERLIPRESSIN ACETATE ingredient
NCE-1 date: 14 September, 2026
Market Authorisation Date: 14 September, 2022
Dosage: POWDER
More Information on Dosage
TERLIVAZ family patents
25. Trulance patent expiration
Treatment: Elevation of intracellular cgmp resulting in increased intestinal fluid and accelerated transit; Chronic idiopathic constipation; Irritable bowel syndrome with constipation
TRULANCE's oppositions filed in EPO
TRULANCE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7799897 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jun, 2022
(3 years ago) | |
| US7041786 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jan, 2028
(2 years from now) | |
| US10011637 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8637451 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Mar, 2022
(3 years ago) | |
| US9919024 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(5 years from now) | |
| US9610321 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(5 years from now) | |
| US12146003 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(8 years from now) | |
| US9925231 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(5 years from now) | |
| US9616097 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Aug, 2032
(6 years from now) | |
| US11142549 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(8 years from now) | |
| US11834521 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(8 years from now) | |
| US11319346 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Mar, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-764) | Jan 24, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jan 19, 2022 |
Drugs and Companies using PLECANATIDE ingredient
NCE-1 date: 19 January, 2021
Market Authorisation Date: 19 January, 2017
Dosage: TABLET
How can I launch a generic of TRULANCE before it's drug patent expiration?
More Information on Dosage
TRULANCE family patents
26. Varubi patent expiration
Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy
VARUBI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7049230 | TERSERA | Method of forming a contact plug in a semiconductor device |
Dec, 2023
(2 years ago) | |
| US7049320 | TERSERA | NK1 antagonists |
Aug, 2028
(2 years from now) | |
| US8178550 | TERSERA | Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor |
Apr, 2027
(1 year, 2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8796299 | TERSERA | NK1 antagonists |
Dec, 2022
(3 years ago) | |
| US7981905 | TERSERA | Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
Apr, 2027
(1 year, 2 months from now) | |
| US8470842 | TERSERA | Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor |
Jan, 2029
(3 years from now) | |
| US8404702 | TERSERA | Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
Apr, 2027
(1 year, 2 months from now) | |
| US9101615 | TERSERA | Intravenous formulations of neurokinin-1 antagonists |
Jul, 2032
(6 years from now) | |
| US7563801 | TERSERA | Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
Apr, 2027
(1 year, 2 months from now) | |
| US8361500 | TERSERA | Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom |
Oct, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 01, 2020 |
Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient
NCE-1 date: 02 September, 2019
Market Authorisation Date: 25 October, 2017
Dosage: EMULSION; TABLET
More Information on Dosage
VARUBI family patents
27. Velsipity patent expiration
Treatment: A method for treating ulcerative colitis by administering estrasimod l-arginine in an amount equivalent to about 2.0 mg of estrasimod; A method for treating ulcerative colitis by administering a thera...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11091435 | PFIZER | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in S1P1 receptor-associated disorders |
Jun, 2036
(10 years from now) | |
| US10301262 | PFIZER | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
Jun, 2036
(10 years from now) | |
| US8580841 | PFIZER | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
Mar, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12377071 | PFIZER | NA |
Jan, 2036
(9 years from now) | |
| US11884626 | PFIZER | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders |
Jun, 2036
(10 years from now) | |
| US11007175 | PFIZER | Methods of treating conditions related to the S1P1 receptor |
Jan, 2036
(9 years from now) | |
| US10676435 | PFIZER | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disorders |
Jun, 2036
(10 years from now) | |
| US9126932 | PFIZER | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
Jul, 2029
(3 years from now) | |
| US12156866 | PFIZER | Methods of treating conditions related to the S1P1 receptor |
Jan, 2036
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2028 |
Drugs and Companies using ETRASIMOD ARGININE ingredient
NCE-1 date: 13 October, 2027
Market Authorisation Date: 12 October, 2023
Dosage: TABLET
More Information on Dosage
VELSIPITY family patents
28. Viberzi patent expiration
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline).; Treatment of pain associated with irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline); Re...
VIBERZI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10213415 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(9 months ago) | |
| US9115091 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(2 years from now) | |
| US8691860 | ABBVIE | Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(2 years from now) | |
| US8609709 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(9 months ago) | |
| US7786158 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(9 months ago) | |
| US7741356 | ABBVIE | Compounds as opioid receptor modulators |
May, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8772325 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(9 months ago) | |
| US9364489 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(2 years from now) | |
| US9789125 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(2 years from now) | |
| US8344011 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(9 months ago) | |
| US12097187 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(7 years from now) | |
| US9205076 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(9 months ago) | |
| US11484527 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(7 years from now) | |
| US9675587 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(7 years from now) | |
| US11007179 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(7 years from now) | |
| US9700542 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(9 months ago) | |
| US11090291 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(7 years from now) | |
| US11311516 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(7 years from now) | |
| US11229627 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(7 years from now) | |
| US10188632 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(7 years from now) | |
| US11160792 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2020 |
Drugs and Companies using ELUXADOLINE ingredient
NCE-1 date: 28 May, 2019
Market Authorisation Date: 27 May, 2015
Dosage: TABLET
How can I launch a generic of VIBERZI before it's drug patent expiration?
More Information on Dosage
VIBERZI family patents
29. Xeljanz patent expiration
Treatment: Treatment of adult patients with moderately to severely active ulcerative colitis (uc); Treatment of rheumatoid arthritis
XELJANZ's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7301023 | PF PRISM CV | Chiral salt resolution |
Dec, 2020
(5 years ago) | |
| US7265221 | PF PRISM CV | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US6965027 | PF PRISM CV | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(2 years ago) | |
| USRE41783 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(a month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7842699 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US6956041 | PF PRISM CV | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US7301023 | PF PRISM CV | Chiral salt resolution |
May, 2022
(3 years ago) | |
| US6965027 | PF PRISM CV | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(2 years ago) | |
| US7091208 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US7265221 | PF PRISM CV | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
|
USRE41783 (Pediatric) | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Jun, 2026
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-135) | Feb 21, 2017 |
| New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
| New Indication(I-761) | Dec 14, 2020 |
| New Indication(I-780) | May 30, 2021 |
| New Product(NP) | Sep 25, 2023 |
| New Patient Population(NPP) | Sep 25, 2023 |
| New Indication(I-879) | Dec 14, 2024 |
| M(M-14) | Feb 21, 2028 |
| Pediatric Exclusivity(PED) | Aug 21, 2028 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
NCE-1 date: 22 August, 2027
Market Authorisation Date: 06 November, 2012
Dosage: TABLET
How can I launch a generic of XELJANZ before it's drug patent expiration?
More Information on Dosage
XELJANZ family patents
30. Xeljanz patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE41783 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(a month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE41783 (Pediatric) | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Jun, 2026
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-135) | Feb 21, 2017 |
| New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
| New Indication(I-761) | Dec 14, 2020 |
| New Indication(I-780) | May 30, 2021 |
| New Product(NP) | Sep 25, 2023 |
| New Patient Population(NPP) | Sep 25, 2023 |
| New Indication(I-879) | Dec 14, 2024 |
| M(M-14) | Feb 21, 2028 |
| Pediatric Exclusivity(PED) | Aug 21, 2028 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
Market Authorisation Date: 25 September, 2020
Dosage: SOLUTION
How can I launch a generic of XELJANZ before it's drug patent expiration?
More Information on Dosage
XELJANZ family patents
31. Xenical patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6004996 (Pediatric) | CHEPLAPHARM | Tetrahydrolipstatin containing compositions |
Jul, 2018
(7 years ago) | |
| US6004996 | CHEPLAPHARM | Tetrahydrolipstatin containing compositions |
Jan, 2018
(8 years ago) | |
Drugs and Companies using ORLISTAT ingredient
Market Authorisation Date: 23 April, 1999
Dosage: CAPSULE
More Information on Dosage
XENICAL family patents
32. Xifaxan patent expiration
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older; Reduction in a subject's risk of experiencing a breakthrough overt hepatic encephalopathy (he) episode; ...
XIFAXAN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8741904 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(a month from now) | |
| US8835452 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 6 months ago) | |
| US8193196 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Sep, 2027
(1 year, 7 months from now) | |
| US8158781 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 6 months ago) | |
| US7612199 | SALIX PHARMS | Polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 6 months ago) | |
| US7902206 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 6 months ago) | |
| US7045620 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
Jun, 2024
(1 year, 6 months ago) | |
| US7906542 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2025
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10456384 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| US10335397 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US9421195 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US8946252 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US7452857 | SALIX PHARMS | Methods of treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
Aug, 2019
(6 years ago) | |
| US8829017 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US8642573 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Oct, 2029
(3 years from now) | |
| US10314828 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US7915275 | SALIX PHARMS | Use of polymorphic forms of rifaximin for medical preparations |
Feb, 2025
(10 months ago) | |
| US7605240 | SALIX PHARMS | Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth |
Aug, 2019
(6 years ago) | |
| US7935799 | SALIX PHARMS | Methods of treating diarrhea caused by small intestinal bacterial overgrowth |
Aug, 2019
(6 years ago) | |
| US10709694 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US10765667 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| US8969398 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Oct, 2029
(3 years from now) | |
| US6861053 | SALIX PHARMS | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
Aug, 2019
(6 years ago) | |
| US8518949 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(a month from now) | |
| US9629828 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US9271968 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(a month from now) | |
| US8158781 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 6 months ago) | |
| US8158644 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 6 months ago) | |
| US7612199 | SALIX PHARMS | Polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 6 months ago) | |
| US8853231 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 6 months ago) | |
| US7045620 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
Jun, 2024
(1 year, 6 months ago) | |
| US8193196 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Sep, 2027
(1 year, 7 months from now) | |
| US10703763 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(a month from now) | |
| US7718608 | SALIX PHARMS | Methods of treating a subject suffering from irritable bowel syndrome |
Aug, 2019
(6 years ago) | |
| US8309569 | SALIX PHARMS | Methods for treating diarrhea-associated irritable bowel syndrome |
Jul, 2029
(3 years from now) | |
| US7902206 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 6 months ago) | |
| US7906542 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2025
(7 months ago) | |
| US7928115 | SALIX PHARMS | Methods of treating travelers diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US11779571 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| US11564912 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 24, 2013 |
| Orphan Drug Exclusivity(ODE) | Mar 24, 2017 |
| New Indication(I-709) | May 27, 2018 |
Drugs and Companies using RIFAXIMIN ingredient
Market Authorisation Date: 24 March, 2010
Dosage: TABLET
How can I launch a generic of XIFAXAN before it's drug patent expiration?
More Information on Dosage
XIFAXAN family patents
33. Zelnorm patent expiration
Treatment: Treatment of irritable bowel syndrome
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5510353 | ALFASIGMA | Certain aminoguanidine compounds, pharmaceutical compositions containing them and their use in treating gastrointestinal motility disorders and disorders associated with cephalic pain |
Apr, 2013
(12 years ago) | |
Drugs and Companies using TEGASEROD MALEATE ingredient
Market Authorisation Date: 24 July, 2002
Dosage: TABLET
More Information on Dosage
ZELNORM family patents
34. Zeposia patent expiration
Treatment: Treatment of moderately to severely active ulcerative colitis (uc) in adults; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting dise...
ZEPOSIA's oppositions filed in EPO
Can you believe ZEPOSIA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11680050 | BRISTOL | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof |
Sep, 2038
(12 years from now) | |
| US8481573 | BRISTOL | Modulators of sphingosine phosphate receptors |
Mar, 2033
(7 years from now) | |
| US8796318 | BRISTOL | Modulators of sphingosine phosphate receptors |
May, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10239846 | BRISTOL | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Nov, 2030
(4 years from now) | |
| US9382217 | BRISTOL | Modulators of sphingosine phosphate receptors |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-860) | May 27, 2024 |
| New Chemical Entity Exclusivity(NCE) | Mar 25, 2025 |
| M(M-309) | Aug 30, 2027 |
Drugs and Companies using OZANIMOD HYDROCHLORIDE ingredient
NCE-1 date: 25 March, 2024
Market Authorisation Date: 25 March, 2020
Dosage: CAPSULE
More Information on Dosage
ZEPOSIA family patents